Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Tripathi, Satyendra Chandra ^a   Matta, Ajay ^b   Kaur, Jatinder ^a   Grigull, Jorg ^b   Chauhan, Shyam Singh ^a   Thakar, Alok ^a   Shukla, Nootan Kumar ^c   Duggal, Ritu ^a   Choudhary, Ajoy Roy ^a   DattaGupta, Siddhartha ^a   Sharma, Mehar Chand ^a   Ralhan, Ranju ^b,d,e   Siu, K W Michael ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b YORK UNIVERSITY   (Canada)

^c INSTITUTE ROTARY CANCER HOSPITAL   (India)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTHYMOSIN ALPHA; DRUG DERIVATIVE; PROTEIN PRECURSOR; THYMOSIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL HYPERPLASIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE FREE SURVIVAL; DISEASE MARKER; DYSPLASIA; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN PRECURSORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMOSIN; YOUNG ADULT;

EID: 79955790476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019213     Document Type: Article

References (53)

1. Haritos AA, Goodall GJ, Horecker BL, (1984) Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc Natl Acad Sci U S A 81: 1008-1011.
2. Dosil M, Alvarez-Fernandez L, Gomez-Marquez J, (1993) Differentiation-linked expression of prothymosin alpha gene in human myeloid leukemic cells. Exp Cell Res 204: 94-101.
3. Eilers M, Schirm S, Bishop JM, (1991) The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J 10: 133-141.
4. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, et al. (2003) Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 299: 223-226.
5. Magdalena C, Dominguez F, Loidi L, Puente JL, (2000) Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer. Br J Cancer 82: 584-590.
6. Orre RS, Cotter MA 2nd, Subramanian C, Robertson ES, (2001) Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro. J Biol Chem 276: 1794-1799.
7. Pineiro A, Cordero OJ, Nogueira M, (2000) Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides 21: 1433-1446.
8. Rodriguez P, Vinuela JE, Alvarez-Fernandez L, Buceta M, Vidal A, et al. (1998) Overexpression of prothymosin alpha accelerates proliferation and retards differentiation in HL-60 cells. Biochem J 331 (Pt 3): 753-761.
9. Wu CG, Habib NA, Mitry RR, Reitsma PH, van Deventer SJ, et al. (1997) Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma. Br J Cancer 76: 1199-1204.
10. Sasaki H, Nonaka M, Fujii Y, Yamakawa Y, Fukai I, et al. (2001) Expression of the prothymosin-a gene as a prognostic factor in lung cancer. Surg Today 31: 936-938.
11. Sasaki H, Sato Y, Kondo S, Fukai I, Kiriyama M, et al. (2001) Expression of the prothymosin alpha mRNA correlated with that of N-myc in neuroblastoma. Cancer Lett 168: 191-195.
12. Tsai YS, Jou YC, Lee GF, Chen YC, Shiau AL, et al. (2009) Aberrant prothymosin-alpha expression in human bladder cancer. Urology 73: 188-192.
13. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, et al. (2007) Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141: 41-50.
14. Jou YC, Tung CL, Tsai YS, Shen CH, Syue-Yi C, et al. (2009) Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma. Urology 74: 951-957.
15. Suzuki S, Takahashi S, Takeshita K, Hikosaka A, Wakita T, et al. (2006) Expression of prothymosin alpha is correlated with development and progression in human prostate cancers. Prostate 66: 463-469.
16. Tzai TS, Tsai YS, Shiau AL, Wu CL, Shieh GS, et al. (2006) Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Urology 67: 294-299.
17. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, et al. (2008) Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 7: 1162-1173.
18. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S, (1998) Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 18: 4779-4786.
19. Franceschi S, Levi F, Dal Maso L, Talamini R, Conti E, et al. (2000) Cessation of alcohol drinking and risk of cancer of the oral cavity and pharynx. Int J Cancer 85: 787-790.
20. Moore SR, Pierce AM, Wilson DF, (2000) 'Oral cancer'-the terminology dilemma. Oral Dis 6: 191-193.
21. Maserejian NN, Joshipura KJ, Rosner BA, Giovannucci E, Zavras AI, (2006) Prospective study of alcohol consumption and risk of oral premalignant lesions in men. Cancer Epidemiol Biomarkers Prev 15: 774-781.
22. Jayalekshmi PA, Gangadharan P, Akiba S, Nair RR, Tsuji M, et al. (2009) Tobacco chewing and female oral cavity cancer risk in Karunagappally cohort, India. Br J Cancer 100: 848-852.
23. Smith EM, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP, (2010) Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes Control.
24. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP, (2010) Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer 5: 4.
25. Hunter KD, Parkinson EK, Harrison PR, (2005) Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135.
26. Warnakulasuriya KA, Ralhan R, (2007) Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco-a review. J Oral Pathol Med 36: 63-77.
27. Warnakulasuriya S, (2009) Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45: 309-316.
28. Bettendorf O, Piffko J, Bankfalvi A, (2004) Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 40: 110-119.
29. Neville BW, Day TA, (2002) Oral cancer and precancerous lesions. CA Cancer J Clin 52: 195-215.
30. Saleh A, Zain RB, Hussaini H, Ng F, Tanavde V, et al. (2010) Transcriptional profiling of oral squamous cell carcinoma using formalin-fixed paraffin-embedded samples. Oral Oncol 46: 379-386.
31. Reibel J, (2003) Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 14: 47-62.
32. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, et al. (2009) iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 8: 300-309.
33. Letsas KP, Frangou-Lazaridis M, (2006) Surfing on prothymosin alpha proliferation and anti-apoptotic properties. Neoplasma 53: 92-96.
34. Romani L, Bistoni F, Montagnoli C, Gaziano R, Bozza S, et al. (2007) Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci 1112: 326-338.
35. Wang F, Arun P, Friedman J, Chen Z, Van Waes C, (2009) Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9: 389-395.
36. Kobayashi T, Wang T, Maezawa M, Kobayashi M, Ohnishi S, et al. (2006) Overexpression of the oncoprotein prothymosin alpha triggers a p53 response that involves p53 acetylation. Cancer Res 66: 3137-3144.
37. Wu CL, Shiau AL, Lin CS, (1997) Prothymosin alpha promotes cell proliferation in NIH3T3 cells. Life Sci 61: 2091-2101.
38. Letsas KP, Frangou-Lazaridis M, Skyrlas A, Tsatsoulis A, Malamou-Mitsi V, (2005) Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions. Pathol Int 55: 694-702.
39. Ben-Yosef T, Yanuka O, Halle D, Benvenisty N, (1998) Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene 17: 165-171.
40. Martini PG, Katzenellenbogen BS, (2001) Regulation of prothymosin alpha gene expression by estrogen in estrogen receptor-containing breast cancer cells via upstream half-palindromic estrogen response element motifs. Endocrinology 142: 3493-3501.
41. Yang CH, Murti A, Baker SJ, Frangou-Lazaridis M, Vartapetian AB, et al. (2004) Interferon induces the interaction of prothymosin-alpha with STAT3 and results in the nuclear translocation of the complex. Exp Cell Res 298: 197-206.
42. Garnier M, Di Lorenzo D, Albertini A, Maggi A, (1997) Identification of estrogen-responsive genes in neuroblastoma SK-ER3 cells. J Neurosci 17: 4591-4599.
43. Lal A, Kawai T, Yang X, Mazan-Mamczarz K, Gorospe M, (2005) Antiapoptotic function of RNA-binding protein HuR effected through prothymosin alpha. EMBO J 24: 1852-1862.
44. Traub F, Jost M, Hess R, Schorn K, Menzel C, et al. (2006) Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab Invest 86: 246-253.
45. Karetsou Z, Martic G, Tavoulari S, Christoforidis S, Wilm M, et al. (2004) Prothymosin alpha associates with the oncoprotein SET and is involved in chromatin decondensation. FEBS Lett 577: 496-500.
46. Karetsou Z, Sandaltzopoulos R, Frangou-Lazaridis M, Lai CY, Tsolas O, et al. (1998) Prothymosin alpha modulates the interaction of histone H1 with chromatin. Nucleic Acids Res 26: 3111-3118.
47. Papamarcaki T, Tsolas O, (1994) Prothymosin alpha binds to histone H1 in vitro. FEBS Lett 345: 71-75.
48. Hapke S, Kessler H, Luber B, Benge A, Hutzler P, et al. (2003) Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem 384: 1073-1083.
49. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, et al. (2003) Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 309: 18-25.
50. Matta A, Tripathi SC, DeSouza LV, Grigull J, Kaur J, et al. (2009) Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 125: 1398-1406.
51. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, et al. (2008) Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res 7: 2078-2087.
52. Matta A, Bahadur S, Duggal R, Gupta SD, Ralhan R, (2007) Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer 7: 169.
53. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R, (2005) Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 42: 97-108.